FDA Approved Treatments
New Drug Approvals
Track the latest FDA-approved medications and their impact on patient care
1 Approvals in 2024
Rezdiffra (resmetirom)
(resmetirom)
Madrigal Pharmaceuticals
4.7/5
Approved: March 14, 2024
Breakthrough TherapyFast TrackPriority Review
Indication
NASH with Liver Fibrosis
Mechanism of Action
Thyroid hormone receptor beta agonist
Clinical Benefit
26% achieved NASH resolution
Patient Population
~1.5 million with F2/F3 fibrosis
List Price
$47,000/year
Key Side Effects
Diarrhea • Nausea • Pruritus
2024 Approval Statistics
Key metrics from this year's FDA approvals
37
Total Approvals
YTD 2024
14
Breakthrough Therapies
38% of total
19
Orphan Drugs
51% of total
92%
First-Cycle Approvals
Record high
Key Trends
- Record number of cell and gene therapies approved
- Increased focus on rare disease treatments
- Faster review times under accelerated pathways
Stay Updated on New Approvals
Get notified when new treatments are approved for conditions you care about